firstscript

Clinical Bulletin

November 27, 2018

Subject: Voluntary Recall of Medications Containing Losartan

Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg, indicated for the treatment of hypertension.[1]

Recall Details

This recall is due to a trace amount of impurity N-nitrosodiethylamine (NDEA) being detected in one lot of Losartan Potassium Hydrochlorothiazide Tablets, which was distributed nationwide beginning October 8, 2018. Details regarding the recalled lot can be found on the U.S. Food & Drug Administration (FDA) Drug Recall website. The FDA recommends patients taking the recalled lot to follow the instructions provided by Sandoz on their website.

For additional recall information, visit: https://www.fda.gov/Safety/Recalls/ucm625492.htm

The Impact

Currently, First Script shows no impact to injured workers due to this recall.

For more information, please contact your Account Manager or Account Pharmacist.

1. https://www.fda.gov/Safety/Recalls/ucm625492.htm

coventry
returning people
to work, to play, to life